Uso medicinal da maconha e outras drogas atualmente ilícitas 221NORDSTROM, B. R., HART, C. L. Assessing cognitive functioning in cannabis users: cannabisuse history an important consideration. Neuropsychopharmacology 31:2798–9, 2006.NUTT, D.J., KING, L. A., NICHOLS, D.E. Effects of Schedule I drug laws on neuroscienceresearch and treatment innovation Nat Rev Neurosci. 14(8): 577-85, 2013.NUTT, D. J., KING, L. A., PHILLIPS, L. D. Drugharms in the UK: a multicriteria decisionanalysis. Lancet 376: 1558-65, 2010.PORCHE, D. J. Legalization of medical marijuana (Cannabis). Am J Mens Health 7(6):449.doi: 10.1177/1557988313504104, 2013.RAMEKERS, J. G., KAUERT, G., RUITENBEEK P. van, THEUNISSEN, E. L., SCHNEI-DER, E., MOELLER, M. R. High-potency Cannabis impairs executive function and inhibitorymotor control. Neuropsychopharmacology 31:2296–303, 2006.RAMAEKERS, J. G., KAUERT, G., THEUNISSEN, E. L., TOENNES, S.W., MOELLER,M. R. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabisusers. J Psychopharmacol 23:266–77, 2009.REINARMAN, C., NUNBERG, H., LANTHIER, F., HEDDELESTON, T. Who are medicalcannabis patients? Population characteristics from nine California assessment clinics. Journal ofPsychoactive Drugs 43(2): 128-135, 2011.ROBBE, D., BUZSAKI, G. Alteration of theta timescale dynamics of hippocampal place cells bya cannabinoid is associated with memory impairment. Journal of Neuroscience 29:12597–12605, 2009.ROBBE, D., MONTGOMERY, S. M., THOME, A., RUEDA-OROZCO, P. E., MC-NAUGHTON, B. L., BUZSAKI, G. Cannabinoids reveal importance of spike timing coordinationin hippocampal function. Nature Neuroscience 9:1526–1533, 2006.ROOM, R., FISCHER, B., HALL, W., LENTON, S., REUTER, P. (2008), “The global cannabiscommission report”, Oxford: Beckley Foundation.ROOM, R., FISCHER, B., HALL, W., LENTON, S., REUTER, P. Cannabis policy: movingbeyond stalemate. Oxford: Oxford University Press, 2010.ROOM, R., REUTER, P. How well do international drug conventions protect public health?Lancet 379: 84-91,2012.RUSSO, E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourageeffects. Br J Pharmacol. 163(7): 1344-64, 2011.SCHULTES, R. E., HOFMANN, A. Plants of the Gods: Their sacred, healing, and hallucinogenicpowers. London: Hutchinson, 1979.SESSA, B., NUTT, D. J. MDMA, Politics and Medical Research: Have we thrown the baby outwith the bathwater? J. Psychopharmacol. 21 (8): 787–791. doi:10.1177/0269881107084738. PMID 17984158, 2007.SEWELL, R. A., HALPERN, J. H., POPE, H. G. Response of cluster headache to psilocybin andLSD. Neurology, 66(12), 1920-2, 2006.SHEWAN, D., DALGARNO, P., REITH, G. Perceived risk and risk reduction among ecstasy users:the role of drug, set, and setting. International Journal of Drug Policy, 10: 431-453, 2000.STRANG, J., BABOR, T., CAULKINS, J., FISCHER, B., FOXCROFT, D., HUMPHREYS,K. Drug Policy and the Public Good: Evidence for EffectiveInterventions. The Lancet 379(9810): 71-83, 2012.
222 Drogas no Brasil – Entre a saúde e a justiçaTHOMPSON, M. R., CALLAGHAN, P. D., HUNT, G. E., CORNISH, J. L., MCGREGOR,I. S. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4-methylenedioxymethamphetamine(‘‘ecstasy’’). Neuroscience 146: 509–514, 2007.VADHAN, N. P., HART, C. L., GORP, W. G. van, HANEY, M., GUNDERSON, E. W.,FOLTIN, R. W. Acute effects of smoked Cannabis on decision-making, as assessed by a modifiedgambling task, in experienced Cannabis users. J. Clin Exp Neuropsychol 29:357-64, 2007.WARD, A. S., COMER, S. D., HANEY, M., FOLTIN, R. W., FISCHMAN, M. W. The effectsof a monetary alternative on Cannabis self-administration. BehavPharmacol 8:275-86, 1997.WILSON, R. I., NICOLL, R. A. Endocannabinoid signaling in the brain. Science 296(5568):678-82, 2002.RELATÓRIO MUNDIAL SOBRE DROGAS, United Nations Offi ce on Drugs and Crime(UNODC), 2009.UNODC. Extent of illicit drug use and health consequences. In World Drug Report (pp. 1–17).New York: United Nations, 2013.USA Department of Veterans Affairs, 2012, OEF/OIF/OND Veterans Coded with PotentialPTSD, Cumulative from FY 2002 – 3rd Qtr FY 2012, Revised December 2012.VOLLENWEIDER, F. X., KOMETER, M. The neurobiology of psychedelic drugs: implicationsfor the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 642-51, 2010.ZINBERG, N., E. DRUG, Set, and SETTING. New Haven: Yale University Press, 1984.
Change language